Description
Dual GIP / GLP-1 receptor agonist for type 2 diabetes and obesity
Tirzepatide is a powerful peptide formulation for reducing appetite and enhancing fat metabolism. Activates GIP and GLP-1 receptors, helping regulate appetite and promoting satiety. Enhances fat oxidation, allowing more efficient burning of stored fat. Also helps regulate blood sugar levels and improves insulin sensitivity.
- Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. PMID: 34186022 | DOI: 10.1016/S0140-6736(21)01324-6
- Nauck MA, et al. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169. PMID: 36050763 | DOI: 10.1186/s12933-022-01604-7
- Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024;15:1431292. PMID: 39114288 | DOI: 10.3389/fendo.2024.1431292
